STI and Vaginitis PCR Testing Market Size, Share, Trends, & Industry Analysis Report By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region – Market Forecast, 2025–2034
Description
The global STI and vaginitis PCR testing market size is expected to reach USD 1,578.43 million by 2034, according to a new study by Polaris Market Research. The report “STI and Vaginitis PCR Testing Size, Share, Trends & Industry Analysis Report: By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The STI and vaginitis PCR testing market focuses on the implementation of advanced diagnostics using polymerase chain reaction (PCR) technology for pathogen specific testing of STIs and different types of vaginal infections. These infections encompass common sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and trichomoniasis, alongside vaginal infections such as bacterial vaginosis and vulvovaginal candidiasis. PCR testing is unique among other testing methods due to its high sensitivity and specificity, and its ability to accurately capture the genetic material of causative organisms, no matter how minute the quantities are. This level of precision is essential for prompt and accurate diagnosis and an intense and precise treatment plan that addresses disease progression and further transmission needs.
The expectations related to this area of testing are particularly optimistic for multiple reasons. The rising prevalence of STIs and vaginitis regionally augments the demand for accurate diagnosis. The advancement in molecular diagnostic tools, as in the case of multiplex PCR assay development, is also accelerating growth in this area. The ability to detect multiple pathogens from a single sample increases both efficiency and provides enhanced diagnostic information for clinicians. Moreover, public awareness and proactive screening campaigns heighten population testing intensity, which is an encouraging trend directed toward explicitly defined sexual and reproductive health. Such changes necessitate accurate and reliable tools for diagnosis and, thereby, purposeful and strategic toward letter accessibility.
STI and Vaginitis PCR Testing Market Report Highlights:
By condition, the sexually transmitted infections (STIs) segment held a larger share in 2024, driven by the persistent high global prevalence of various STIs, many of which are asymptomatic, and the crucial need for accurate, sensitive diagnostic tools such as PCR for widespread screening and public health management.
By test type, the STI PCR panels segment dominated the market in 2024. The dominance is primarily attributed to the critical requirement for accurate and sensitive detection of a broad range of sexually transmitted pathogens, often simultaneously through multiplex panels, which are essential for comprehensive diagnosis and treatment guidance.
By end use, the diagnostic laboratories segment held the largest share in 2024, owing to their specialized infrastructure, high-throughput capabilities, and the expertise necessary for processing a large volume of complex molecular diagnostic tests from various healthcare settings.
By region, North America holds a substantial share of the STI and vaginitis PCR testing market. This is largely attributed to the robust healthcare infrastructure, high awareness regarding sexual health, and the early adoption of advanced diagnostic technologies, including PCR-based assays. The Asia Pacific STI and vaginitis PCR testing market is anticipated to exhibit a significant growth rate during the forecast period. This growth is primarily fueled by improving healthcare infrastructure, increasing disposable incomes, and a rising awareness about sexual and reproductive health in countries such as China and India.
A few key players in the market include Hologic, Inc.; BD (Becton, Dickinson and Company); bioMérieux; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Qiagen; OraSure Technologies; and SpeeDx Pty Ltd. Additionally, some key entities operate under larger parent organizations, such as Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.).
Polaris Market Research has segmented the STI and vaginitis PCR testing market report on the basis of condition, test type, end use, and region:
By Condition Outlook (Revenue – USD Million, 2020–2034)
Sexually Transmitted Infections (STIs)
Chlamydia
Gonorrhea
Trichomoniasis
Herpes Simplex Virus (HSV-1 & HSV-2)
Human Papillomavirus (HPV)
Syphilis
Other
Vaginal Infections
Bacterial Vaginosis
Vulvovaginal Candidiasis
Other
By Test Type Outlook (Revenue – USD Million, 2020–2034)
STI PCR Panels
Vaginitis PCR Panels
By End Use Outlook (Revenue – USD Million, 2020–2034)
Hospitals & Clinics
Diagnostic Laboratories
Homecare/At-home Testing
Others
By Regional Outlook (Revenue – USD Million, 2020–2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
The STI and vaginitis PCR testing market focuses on the implementation of advanced diagnostics using polymerase chain reaction (PCR) technology for pathogen specific testing of STIs and different types of vaginal infections. These infections encompass common sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and trichomoniasis, alongside vaginal infections such as bacterial vaginosis and vulvovaginal candidiasis. PCR testing is unique among other testing methods due to its high sensitivity and specificity, and its ability to accurately capture the genetic material of causative organisms, no matter how minute the quantities are. This level of precision is essential for prompt and accurate diagnosis and an intense and precise treatment plan that addresses disease progression and further transmission needs.
The expectations related to this area of testing are particularly optimistic for multiple reasons. The rising prevalence of STIs and vaginitis regionally augments the demand for accurate diagnosis. The advancement in molecular diagnostic tools, as in the case of multiplex PCR assay development, is also accelerating growth in this area. The ability to detect multiple pathogens from a single sample increases both efficiency and provides enhanced diagnostic information for clinicians. Moreover, public awareness and proactive screening campaigns heighten population testing intensity, which is an encouraging trend directed toward explicitly defined sexual and reproductive health. Such changes necessitate accurate and reliable tools for diagnosis and, thereby, purposeful and strategic toward letter accessibility.
STI and Vaginitis PCR Testing Market Report Highlights:
By condition, the sexually transmitted infections (STIs) segment held a larger share in 2024, driven by the persistent high global prevalence of various STIs, many of which are asymptomatic, and the crucial need for accurate, sensitive diagnostic tools such as PCR for widespread screening and public health management.
By test type, the STI PCR panels segment dominated the market in 2024. The dominance is primarily attributed to the critical requirement for accurate and sensitive detection of a broad range of sexually transmitted pathogens, often simultaneously through multiplex panels, which are essential for comprehensive diagnosis and treatment guidance.
By end use, the diagnostic laboratories segment held the largest share in 2024, owing to their specialized infrastructure, high-throughput capabilities, and the expertise necessary for processing a large volume of complex molecular diagnostic tests from various healthcare settings.
By region, North America holds a substantial share of the STI and vaginitis PCR testing market. This is largely attributed to the robust healthcare infrastructure, high awareness regarding sexual health, and the early adoption of advanced diagnostic technologies, including PCR-based assays. The Asia Pacific STI and vaginitis PCR testing market is anticipated to exhibit a significant growth rate during the forecast period. This growth is primarily fueled by improving healthcare infrastructure, increasing disposable incomes, and a rising awareness about sexual and reproductive health in countries such as China and India.
A few key players in the market include Hologic, Inc.; BD (Becton, Dickinson and Company); bioMérieux; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Qiagen; OraSure Technologies; and SpeeDx Pty Ltd. Additionally, some key entities operate under larger parent organizations, such as Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.).
Polaris Market Research has segmented the STI and vaginitis PCR testing market report on the basis of condition, test type, end use, and region:
By Condition Outlook (Revenue – USD Million, 2020–2034)
Sexually Transmitted Infections (STIs)
Chlamydia
Gonorrhea
Trichomoniasis
Herpes Simplex Virus (HSV-1 & HSV-2)
Human Papillomavirus (HPV)
Syphilis
Other
Vaginal Infections
Bacterial Vaginosis
Vulvovaginal Candidiasis
Other
By Test Type Outlook (Revenue – USD Million, 2020–2034)
STI PCR Panels
Vaginitis PCR Panels
By End Use Outlook (Revenue – USD Million, 2020–2034)
Hospitals & Clinics
Diagnostic Laboratories
Homecare/At-home Testing
Others
By Regional Outlook (Revenue – USD Million, 2020–2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
- 4. Global STI and Vaginitis PCR Testing Market Insights
- 4.1. STI and Vaginitis PCR Testing Market – Market Snapshot
- 4.2. STI and Vaginitis PCR Testing Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of STIs and Vaginitis
- 4.2.1.2. Technological Advancements in Molecular Diagnostics
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost and infrastructure barriers
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. STI and Vaginitis PCR Testing Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global STI and Vaginitis PCR Testing Market, by Condition
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 5.3. Sexually Transmitted Infections (STIs)
- 5.3.1. Global STI and Vaginitis PCR Testing Market, by Sexually Transmitted Infections (STIs), by Region, 2020–2034 (USD Million)
- 5.3.2. Chlamydia
- 5.3.3. Gonorrhea
- 5.3.4. Trichomoniasis
- 5.3.5. Herpes Simplex Virus (HSV-1 & HSV-2)
- 5.3.6. Human Papillomavirus (HPV)
- 5.3.7. Syphilis
- 5.3.8. Other
- 5.4. Vaginal Infections
- 5.4.1. Global STI and Vaginitis PCR Testing Market, by Vaginal Infections, by Region, 2020–2034 (USD Million)
- 5.4.2. Bacterial Vaginosis
- 5.4.3. Vulvovaginal Candidiasis
- 5.4.4. Other
- 6. Global STI and Vaginitis PCR Testing Market, by Test Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 6.3. STI PCR Panels
- 6.3.1. Global STI and Vaginitis PCR Testing Market, by STI PCR Panels, by Region, 2020–2034 (USD Million)
- 6.4. Vaginitis PCR Panels
- 6.4.1. Global STI and Vaginitis PCR Testing Market, by Vaginitis PCR Panels, by Region, 2020–2034 (USD Million)
- 7. Global STI and Vaginitis PCR Testing Market, by End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 7.3. Hospitals & Clinics
- 7.3.1. Global STI and Vaginitis PCR Testing Market, by Hospitals & Clinics, by Region, 2020–2034 (USD Million)
- 7.4. Diagnostic Laboratories
- 7.4.1. Global STI and Vaginitis PCR Testing Market, by Diagnostic Laboratories, by Region, 2020–2034 (USD Million)
- 7.5. Homecare/At-home Testing
- 7.5.1. Global STI and Vaginitis PCR Testing Market, by Homecare/At-home Testing, by Region, 2020–2034 (USD Million)
- 7.6. Others
- 7.6.1. Global STI and Vaginitis PCR Testing Market, by Others, by Region, 2020–2034 (USD Million)
- 8. Global STI and Vaginitis PCR Testing Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. STI and Vaginitis PCR Testing Market Assessment, By Geography, 2020–2034 (USD Million)
- 8.3. STI and Vaginitis PCR Testing Market – North America
- 8.3.1. North America: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.3.2. North America: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.3.3. North America: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.3.4. STI and Vaginitis PCR Testing Market – U.S.
- 8.3.4.1. U.S.: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.3.4.2. U.S.: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.3.4.3. U.S.: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.3.5. STI and Vaginitis PCR Testing Market – Canada
- 8.3.5.1. Canada: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.3.5.2. Canada: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.3.5.3. Canada: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4. STI and Vaginitis PCR Testing Market – Europe
- 8.4.1. Europe: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.2. Europe: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.3. Europe: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.4. STI and Vaginitis PCR Testing Market – UK
- 8.4.4.1. UK: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.4.2. UK: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.4.3. UK: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.5. STI and Vaginitis PCR Testing Market – France
- 8.4.5.1. France: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.5.2. France: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.5.3. France: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.6. STI and Vaginitis PCR Testing Market – Germany
- 8.4.6.1. Germany: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.6.2. Germany: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.6.3. Germany: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.7. STI and Vaginitis PCR Testing Market – Italy
- 8.4.7.1. Italy: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.7.2. Italy: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.7.3. Italy: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.8. STI and Vaginitis PCR Testing Market – Spain
- 8.4.8.1. Spain: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.8.2. Spain: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.8.3. Spain: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.9. STI and Vaginitis PCR Testing Market – Netherlands
- 8.4.9.1. Netherlands: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.9.2. Netherlands: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.9.3. Netherlands: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.10. STI and Vaginitis PCR Testing Market – Russia
- 8.4.10.1. Russia: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.10.2. Russia: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.10.3. Russia: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.4.11. STI and Vaginitis PCR Testing Market – Rest of Europe
- 8.4.11.1. Rest of Europe: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.4.11.2. Rest of Europe: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.4.11.3. Rest of Europe: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5. STI and Vaginitis PCR Testing Market – Asia Pacific
- 8.5.1. Asia Pacific: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.2. Asia Pacific: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.3. Asia Pacific: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.4. STI and Vaginitis PCR Testing Market – China
- 8.5.4.1. China: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.4.2. China: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.4.3. China: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.5. STI and Vaginitis PCR Testing Market – India
- 8.5.5.1. India: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.5.2. India: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.5.3. India: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.6. STI and Vaginitis PCR Testing Market – Malaysia
- 8.5.6.1. Malaysia: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.6.2. Malaysia: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.6.3. Malaysia: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.7. STI and Vaginitis PCR Testing Market – Japan
- 8.5.7.1. Japan: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.7.2. Japan: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.7.3. Japan: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.8. STI and Vaginitis PCR Testing Market – Indonesia
- 8.5.8.1. Indonesia: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.8.2. Indonesia: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.8.3. Indonesia: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.9. STI and Vaginitis PCR Testing Market – South Korea
- 8.5.9.1. South Korea: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.9.2. South Korea: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.9.3. South Korea: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.10. STI and Vaginitis PCR Testing Market – Australia
- 8.5.10.1. Australia: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.10.2. Australia: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.10.3. Australia: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.5.11. STI and Vaginitis PCR Testing Market – Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.5.11.2. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.5.11.3. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6. STI and Vaginitis PCR Testing Market – Middle East & Africa
- 8.6.1. Middle East & Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.2. Middle East & Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.3. Middle East & Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6.4. STI and Vaginitis PCR Testing Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.4.2. Saudi Arabia: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.4.3. Saudi Arabia: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6.5. STI and Vaginitis PCR Testing Market – UAE
- 8.6.5.1. UAE: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.5.2. UAE: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.5.3. UAE: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6.6. STI and Vaginitis PCR Testing Market – Israel
- 8.6.6.1. Israel: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.6.2. Israel: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.6.3. Israel: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6.7. STI and Vaginitis PCR Testing Market – South Africa
- 8.6.7.1. South Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.7.2. South Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.7.3. South Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.6.8. STI and Vaginitis PCR Testing Market – Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.6.8.2. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.6.8.3. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.7. STI and Vaginitis PCR Testing Market – Latin America
- 8.7.1. Latin America: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.7.2. Latin America: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.7.3. Latin America: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.7.4. STI and Vaginitis PCR Testing Market – Mexico
- 8.7.4.1. Mexico: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.7.4.2. Mexico: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.7.4.3. Mexico: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.7.5. STI and Vaginitis PCR Testing Market – Brazil
- 8.7.5.1. Brazil: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.7.5.2. Brazil: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.7.5.3. Brazil: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.7.6. STI and Vaginitis PCR Testing Market – Argentina
- 8.7.6.1. Argentina: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.7.6.2. Argentina: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.7.6.3. Argentina: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 8.7.7. STI and Vaginitis PCR Testing Market – Rest of Latin America
- 8.7.7.1. Rest of Latin America: STI and Vaginitis PCR Testing Market, by Condition, 2020–2034 (USD Million)
- 8.7.7.2. Rest of Latin America: STI and Vaginitis PCR Testing Market, by Test Type, 2020–2034 (USD Million)
- 8.7.7.3. Rest of Latin America: STI and Vaginitis PCR Testing Market, by End Use, 2020–2034 (USD Million)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. BD (Becton, Dickinson and Company)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. bioMérieux
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Cepheid (Danaher)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. F. Hoffmann-La Roche Ltd
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Hologic, Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Luminex Corporation (DiaSorin S.p. A.)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. OraSure Technologies
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Qiagen
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. SpeeDx Pty Ltd
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Thermo Fisher Scientific Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
